Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abp 215 + carboplatin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**ABP 215 + carboplatin + paclitaxel** is a combination regimen used in oncology, particularly for advanced non-squamous non-small cell lung cancer (NSCLC). ABP 215 is a biosimilar of bevacizumab (branded as Avastin), a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis, the formation of new blood vessels necessary for tumor growth. Carboplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis, and paclitaxel is a microtubule-stabilizing chemotherapeutic that inhibits cell division. This combination is administered intravenously and has efficacy and safety comparable to regimens using reference bevacizumab in key cancer indications, especially NSCLC.
- Brand names
- MVASI
- Other names
- abp 215 + carboplatin + paclitaxel
02
Targets
Beyond the preview
Go deeper on abp 215 + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abp 215 + carboplatin + paclitaxel.